


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:55Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407138" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407138</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>kidney360</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="editorial" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney360</journal-id><journal-id journal-id-type="iso-abbrev">Kidney360</journal-id><journal-id journal-id-type="pmc-domain-id">4060</journal-id><journal-id journal-id-type="pmc-domain">kidney360</journal-id><journal-id journal-id-type="publisher-id">Kidney360</journal-id><journal-title-group><journal-title>Kidney360</journal-title></journal-title-group><issn pub-type="epub">2641-7650</issn><publisher><publisher-name>American Society of Nephrology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407138</article-id><article-id pub-id-type="pmcid-ver">PMC12407138.1</article-id><article-id pub-id-type="pmcaid">12407138</article-id><article-id pub-id-type="pmcaiid">12407138</article-id><article-id pub-id-type="pmid">40875507</article-id><article-id pub-id-type="doi">10.34067/KID.0000000877</article-id><article-id pub-id-type="publisher-id">K360-2025-000497</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Inhibition of Activin A Signaling by Follistatin Alleviates Diabetic Kidney Disease Burden</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0982-2484</contrib-id><name name-style="western"><surname>Bevilaqua Rangel</surname><given-names initials="&#xC9;">&#201;rika</given-names></name><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="http://credit.niso.org/contributor-roles/funding-acquisition/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="http://credit.niso.org/contributor-roles/validation/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/visualization/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><aff>Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, S&#227;o Paulo, Brazil and Nephrology Division, Federal University of S&#227;o Paulo, S&#227;o Paulo, Brazil</aff></contrib-group><author-notes><corresp><bold>Correspondence:</bold> Dr. &#201;rika Bevilaqua Rangel, email: <email>erikabr@uol.com.br</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>8</month><year>2025</year></pub-date><volume>6</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">496170</issue-id><fpage>1251</fpage><lpage>1253</lpage><pub-history><event event-type="pmc-release"><date><day>28</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="kidney360-6-1251.pdf"/><self-uri xlink:href="kidney360-6-1251.pdf"/><related-article related-article-type="companion" xml:lang="en" xlink:title="research-article" journal-id="Kidney360" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12407135"><article-title>Activin A Antagonism with Follistatin Reduces Kidney Fibrosis, Injury, and Cellular Senescence-Associated Inflammation in Murine Diabetic Kidney Disease</article-title><volume>6</volume><issue>8</issue><date><day>28</day><month>3</month><year>2025</year></date><fpage>1278</fpage><lpage>1291</lpage><source>Kidney360</source><pub-id pub-id-type="doi">10.34067/KID.0000000776</pub-id><pub-id pub-id-type="pmcid">PMC12407135</pub-id><pub-id pub-id-type="pmid">40152935</pub-id></related-article><kwd-group><kwd>chronic dialysis</kwd><kwd>CKD</kwd><kwd>diabetes mellitus</kwd><kwd>diabetic nephropathy</kwd><kwd>kidney transplantation</kwd></kwd-group><funding-group><award-group id="award1"><funding-source xlink:href="https://doi.org/10.13039/501100001807">Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de S&#227;o Paulo</funding-source><award-id>2021/02216-7</award-id><principal-award-recipient>&#201;rika Bevilaqua Rangel</principal-award-recipient></award-group><award-group id="award2"><funding-source xlink:href="https://doi.org/10.13039/501100003593">Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico</funding-source><award-id>403252/2022-9</award-id><principal-award-recipient>&#201;rika Bevilaqua Rangel</principal-award-recipient></award-group></funding-group><funding-group><award-group id="sp1"><funding-source>Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de S&#227;o Paulo</funding-source><award-id rid="sp1">2021/02216-7</award-id></award-group></funding-group><funding-group><award-group id="sp2"><funding-source>Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico</funding-source><award-id rid="sp2">403252/2022-9</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="0"/><ref-count count="10"/><page-count count="3"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>Read-along</meta-name><meta-value>YES</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Diabetic kidney disease (DKD) is the leading cause of ESKD worldwide.<sup><xref rid="B1" ref-type="bibr">1</xref></sup> It is a multifactorial disorder characterized by dysregulation of several biologic pathways, including inflammation, oxidative stress, cell death, autophagy, senescence, and fibrosis.<sup><xref rid="B2" ref-type="bibr">2</xref></sup> These disruptions ultimately lead to structural and functional alterations in kidney compartments, contributing to the progression and burden of DKD.</p><p>Although lifestyle modifications and multitargeted therapies&#8212;including agents that address metabolic disturbances, hemodynamic changes, and inflammation, such as renin-angiotensin system blockers, sodium-glucose cotransporter 2 inhibitors, the mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide-1 receptor agonists&#8212;are widely recommended,<sup><xref rid="B3" ref-type="bibr">3</xref></sup> DKD frequently continues to progress. Thus, identifying novel therapeutic strategies to complement existing treatments is of paramount importance to halt DKD progression more effectively.</p><p>Senescence plays a central biologic role in aging, a known risk factor for chronic diseases such as cancer, cardiovascular and kidney diseases, diabetes mellitus, and neurodegenerative disorders.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> It is triggered by epigenetic factors, telomere attrition, DNA damage, and mitochondrial dysfunction, leading to the accumulation of reactive oxygen species. These alterations contribute to nutrient signaling dysfunction, chronic inflammation, stem cell exhaustion, and proteostatic imbalance, including the accumulation of misfolded or aggregated protein and impaired protein folding protein and degradation.</p><p>Two primary signaling pathways regulate senescence-induced cell arrest: the p16<sup>INK4a</sup>/Rb and p53/p21<sup>CIP1</sup> pathway, both of which converge on the repression of cyclin-dependent kinase4/6. A hallmark of senescent cells is the senescence-associated secretory phenotype (SASP), which mediates many of their cell-extrinsic effects in an autocrine and paracrine. SASP promotes the recruitment and activation of both adaptive and innate immune cells, contributing to chronic low-grade inflammation&#8212;termed inflammaging&#8212;and tissue fibrosis.<sup><xref rid="B4" ref-type="bibr">4</xref></sup> In addition, TGF-<italic toggle="yes">&#946;</italic> can propagate the senescence phenotype to neighboring cells though paracrine signaling.</p><p>Within this context, activin A, a member of the TGF-<italic toggle="yes">&#946;</italic> superfamily, has been implicated in multiple fibrotic processes, including epithelial-mesenchymal transition and fibroblast-myofibroblast transformation, leading to extracellular matrix deposition<sup><xref rid="B5" ref-type="bibr">5</xref></sup> and the release of inflammatory cytokines.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Circulating activin A has also been associated with senescence and SASP, contributing not only to aging but also to frailty and poor postsurgical outcomes.<sup><xref rid="B7" ref-type="bibr">7</xref></sup></p><p>Consistent with these findings, Bian <italic toggle="yes">et al.</italic> reported elevated plasma levels of activin A in patients with DKD, which inversely correlated with eGFR.<sup><xref rid="B8" ref-type="bibr">8</xref></sup> In addition, urinary activin A levels were associated with albuminuria, prompting further investigation into activin A as a therapeutic target for reducing inflammation, senescence, and fibrosis in DKD.</p><p>In this issue, Bian <italic toggle="yes">et al.</italic> evaluated the therapeutic potential of follistatin, a natural activin A antagonist, in C57BLKS/JLepr (db/db) mice treated with angiotensin II <italic toggle="yes">via</italic> subcutaneous osmotic mini pumps (1000 g/kg per minute).<sup><xref rid="B9" ref-type="bibr">9</xref></sup> This well-established preclinical model of type 2 diabetes mellitus and DKD recapitulates key features of the disease, including glomerular and tubular injury and albuminuria. The authors also assessed the effects of follistatin on high glucose-treated human monocytes, renal fibroblasts, and renal tubular epithelial cells.</p><p>Follistatin is a secreted glycoprotein belonging to the secreted protein acidic and rich in cysteine, mainly secreted by mesenchymal stem cells.<sup><xref rid="B10" ref-type="bibr">10</xref></sup> It modulates inflammation and immune responses, influencing cell survival, proliferation, differentiation, and migration. However, its role in kidney disease remains underexplored.</p><p>Bian <italic toggle="yes">et al.</italic> administered two intraperitoneal injections of 5 <italic toggle="yes">&#181;</italic>g of follistatin to db/db mice on days 15 and 18 after angiotensin II pump implantation, with euthanasia on day 28.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Follistatin-treated mice exhibited reduced glomerular injury and lower albuminuria, while plasma creatinine and tubular injury were similar to untreated mice. Follistatin upregulated nephrin and Wilm's tumor 1 and downregulated kidney injury molecule-1 and Mac-2, suggesting preservation of podocyte markers and anti-inflammatory effects.</p><p>Furthermore, follistatin reduced circulating activin A levels and suppressed renal gene expression in diabetic mice treated with angiotensin II. It also decreased fibrotic markers (tenascin-C, collagen 1, and collagen 4), the senescent markers p19<sup>CDKN2D</sup>, and inflammatory markers (TNF-<italic toggle="yes">&#945;</italic>, IL-1<italic toggle="yes">&#946;</italic>, IL-6, and matrix metalloproteinase-2). Renal infiltration of inflammatory cells was also attenuated, with fewer F4/80-positive macrophages and downregulation of monocyte chemoattractant protein-1, toll-like receptor 4, NF kappa-light-chain-enhancer of activated B cells (NF-&#954;B), CD45, and absent in melanoma 2 inflammasome. Follistatin also shifted the macrophage profile toward an anti-inflammatory phenotype by reducing M1 markers CD38 and CD86.</p><p><italic toggle="yes">In vitro</italic>, follistatin (750 ng/ml) suppressed fibrotic activation in activin A (20 ng/ml)&#8211;treated renal fibroblasts, cultured under high-glucose conditions, as evidenced by reduced expression of <italic toggle="yes">&#945;</italic>-smooth muscle actin, collagen 1, fibronectin, and collagen 4. Re-exposure to activin A reversed these effects, underscoring its profibrotic role.</p><p>In the phorbol-12-myristate-13-acetate&#8211;induced human macrophages (phorbol-12-myristate-13-acetate/U937) pretreated with high glucose and LPS (100 ng/ml), follistatin (500 or 750 ng/ml) treatment for 48 hours reduced the number of cells expressing NF-&#954;B and downregulated gene expression of NF-&#954;B, toll-like receptor 4, absent in melanoma 2, IL-1<italic toggle="yes">&#946;</italic>, and IL-6, along with reduced Activin A secretion.</p><p>Collectively, these findings support the therapeutic potential of follistatin in DKD (Figure <xref rid="fig1" ref-type="fig">1</xref>). Future preclinical studies should assess its long-term efficacy and explore its application in other CKD models, including acute-on-chronic kidney injury, either as monotherapy or in combination with other agents targeting inflammatory, senescence-related, and fibrotic signaling pathways. From a clinical perspective, monitoring activin A in response to pharmacologic and nonpharmacologic interventions could help establish its role as a biomarker for DKD progression and treatment response. Furthermore, clinical trials evaluating the safety and efficacy of follistatin in patients with DKD are warranted.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p><bold>Inhibition of activin A signaling by follistatin alleviates DKD burden.</bold> CDK, cyclin-dependent kinase; DKD, diabetic kidney disease; SASP, senescence-associated secretory phenotype; WT-1, Wilm's tumor 1.</p></caption><graphic position="float" orientation="portrait" xlink:href="kidney360-6-1251-g001.jpg"/></fig></body><back><ack><title>Acknowledgments</title><p>The content of this article reflects the personal experience and views of the author and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or <italic toggle="yes">Kidney360</italic>. Responsibility for the information and views expressed herein lies entirely with the author.</p></ack><fn-group><fn fn-type="other"><p>See related article, &#8220;Activin A Antagonism with Follistatin Reduces Kidney Fibrosis, Injury, and Cellular Senescence-Associated Inflammation in Murine Diabetic Kidney Disease,&#8221; on pages 1278&#8211;1291.</p></fn></fn-group><sec sec-type="COI-statement"><title>Disclosures</title><p>Disclosure forms, as provided by each author, are available with the online version of the article at <ext-link xlink:href="http://links.lww.com/KN9/B104" ext-link-type="uri">http://links.lww.com/KN9/B104</ext-link>.</p></sec><sec sec-type="funding"><title>Funding</title><p>&#201;. Bevilaqua Rangel: Funda&#231;&#227;o de Amparo &#224; Pesquisa do Estado de S&#227;o Paulo (2021/02216-7) and Conselho Nacional de Desenvolvimento Cient&#237;fico e Tecnol&#243;gico (403252/2022-9).</p></sec><sec sec-type="author-contributions"><title>Author Contributions</title><p><bold>Conceptualization:</bold> &#201;rika Bevilaqua Rangel.</p><p><bold>Funding acquisition:</bold> &#201;rika Bevilaqua Rangel.</p><p><bold>Validation:</bold> &#201;rika Bevilaqua Rangel.</p><p><bold>Visualization:</bold> &#201;rika Bevilaqua Rangel.</p><p><bold>Writing &#8211; original draft:</bold> &#201;rika Bevilaqua Rangel.</p><p><bold>Writing &#8211; review &amp; editing:</bold> &#201;rika Bevilaqua Rangel.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossing</surname><given-names>P</given-names></name><name name-style="western"><surname>Caramori</surname><given-names>ML</given-names></name><name name-style="western"><surname>Chan</surname><given-names>JCN</given-names></name>, <etal/></person-group>. <article-title>Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence</article-title>. <source>Kidney Int.</source><year>2022</year>;<volume>102</volume>(<issue>5</issue>):<fpage>990</fpage>&#8211;<lpage>999</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.kint.2022.06.013</pub-id><pub-id pub-id-type="pmid">36272755</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gembillo</surname><given-names>G</given-names></name><name name-style="western"><surname>Ingrasciotta</surname><given-names>Y</given-names></name><name name-style="western"><surname>Crisafulli</surname><given-names>S</given-names></name>, <etal/></person-group>. <article-title>Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia</article-title>. <source>Int J Mol Sci.</source><year>2021</year>;<volume>22</volume>(<issue>9</issue>):<fpage>4824</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms22094824</pub-id><pub-id pub-id-type="pmid">34062938</pub-id><pub-id pub-id-type="pmcid">PMC8124790</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabre</surname><given-names>L</given-names></name><name name-style="western"><surname>Pedregosa-Miguel</surname><given-names>JF</given-names></name><name name-style="western"><surname>Rangel</surname><given-names>&#201;B</given-names></name></person-group>. <article-title>Proteinuric and non-proteinuric diabetic kidney disease: different presentations of the same disease?</article-title><source>Diabetology.</source><year>2024</year>;<volume>5</volume>(<issue>4</issue>):<fpage>389</fpage>&#8211;<lpage>405</lpage>. doi:<pub-id pub-id-type="doi">10.3390/diabetology5040030</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McHugh</surname><given-names>D</given-names></name><name name-style="western"><surname>Gil</surname><given-names>J</given-names></name></person-group>. <article-title>Senescence and aging: causes, consequences, and therapeutic avenues</article-title>. <source>J Cell Biol.</source><year>2018</year>;<volume>217</volume>(<issue>1</issue>):<fpage>65</fpage>&#8211;<lpage>77</lpage>. doi:<pub-id pub-id-type="doi">10.1083/jcb.201708092</pub-id><pub-id pub-id-type="pmid">29114066</pub-id><pub-id pub-id-type="pmcid">PMC5748990</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastos</surname><given-names>VAF</given-names></name><name name-style="western"><surname>Fujimura</surname><given-names>PT</given-names></name><name name-style="western"><surname>Souza</surname><given-names>AGd</given-names></name>, <etal/></person-group>. <article-title>Activin A inhibitory peptides suppress fibrotic pathways by targeting epithelial-mesenchymal transition and fibroblast-myofibroblast transformation in idiopathic pulmonary fibrosis</article-title>. <source>Int J Mol Sci.</source><year>2025</year>;<volume>26</volume>(<issue>6</issue>):<fpage>2705</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms26062705</pub-id><pub-id pub-id-type="pmid">40141346</pub-id><pub-id pub-id-type="pmcid">PMC11942258</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kundra</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>R</given-names></name><name name-style="western"><surname>Pasricha</surname><given-names>C</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>P</given-names></name><name name-style="western"><surname>Gurjeet Singh</surname><given-names>T</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R</given-names></name></person-group>. <article-title>Pathological insights into activin A: molecular underpinnings and therapeutic prospects in various diseases</article-title>. <source>Int Immunopharmacol.</source><year>2024</year>;<volume>139</volume>:<fpage>112709</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.intimp.2024.112709</pub-id><pub-id pub-id-type="pmid">39032467</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schafer</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>The senescence-associated secretome as an indicator of age and medical risk</article-title>. <source>JCI Insight.</source><year>2020</year>;<volume>5</volume>(<issue>12</issue>):<fpage>e133668</fpage>. doi:<pub-id pub-id-type="doi">10.1172/jci.insight.133668</pub-id><pub-id pub-id-type="pmid">32554926</pub-id><pub-id pub-id-type="pmcid">PMC7406245</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>X</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>TP</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <etal/></person-group>. <article-title>Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy</article-title>. <source>BMJ Open Diabetes Res Care.</source><year>2019</year>;<volume>7</volume>(<issue>1</issue>):<fpage>e000720</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmjdrc-2019-000720</pub-id><pub-id pub-id-type="pmcid">PMC6936543</pub-id><pub-id pub-id-type="pmid">31908790</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bian</surname><given-names>X</given-names></name><name name-style="western"><surname>Snow</surname><given-names>ZK</given-names></name><name name-style="western"><surname>Zinn</surname><given-names>CJ</given-names></name>, <etal/></person-group>. <article-title>Activin A antagonism with follistatin reduces kidney fibrosis, injury, and cellular senescence-associated inflammation in murine diabetic kidney disease</article-title>. <source>Kidney360.</source><year>2025</year>;<volume>6</volume>(<issue>8</issue>):<fpage>1278</fpage>&#8211;<lpage>1291</lpage>. doi:<pub-id pub-id-type="doi">10.34067/KID.0000000776</pub-id><pub-id pub-id-type="pmid">40152935</pub-id><pub-id pub-id-type="pmcid">PMC12407135</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>MI</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name></person-group>. <article-title>Follistatin-like protein 1: implications for renal disease progression</article-title>. <source>J Pharmacol Exp Ther.</source><year>2025</year>;<volume>392</volume>(<issue>5</issue>):<fpage>103564</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpet.2025.103564</pub-id><pub-id pub-id-type="pmid">40239460</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>